直接磁共振引导下经会阴前列腺穿刺活检的新型磁共振安全机器人装置的安全性与可行性
首个人体试验评估新型磁共振安全机器人装置MrBot行直接磁共振引导下经会阴前列腺穿刺活检的安全性与可行性。5名前列腺特异性抗原升高、既往穿刺阴性且磁共振发现可疑癌灶的男性接受靶向及六分区穿刺,机器人基于磁共振的靶向精度为2.55毫米、垂直于针的精度为1.59毫米,2例需留置导尿管,无其他并发症。作者认为该操作看似安全可行,可精准靶向磁共振显示的有临床意义前列腺癌,但需进一步研究评估疗效。
要点
- 5名男性接受MrBot直接磁共振引导下经会阴前列腺穿刺活检,2例术后需留置导尿管,无其他并发症。
- 30个穿刺位点中,机器人基于磁共振的靶向精度为2.55毫米,垂直于针的精度为1.59毫米。
- 穿刺证实2例存在有临床意义的前列腺癌,作者认为该操作安全可行,但需进一步研究评估疗效。
核心结论
- 机器人辅助磁共振引导下前列腺穿刺活检看似安全可行,能精准靶向磁共振显示的有临床意义前列腺癌(半径≥5毫米,0.5立方厘米)。
- 直接在可疑癌灶确认针尖位置可能优于融合技术,并提高阴性活检的可信度。
- 需进一步研究评估该方法的疗效。
研究设计与样本
- 首个人体试验,评估新型磁共振安全机器人装置MrBot行直接磁共振引导下经会阴前列腺穿刺活检的安全性与可行性,并确定靶向精度。
- 纳入前列腺特异性抗原升高、既往前列腺穿刺阴性且磁共振发现可疑癌灶的男性。
- 对可疑癌灶及六分区位置进行穿刺。
主要发现
- 5名男性接受MrBot穿刺活检。
- 2名男性术后需留置导尿管,无其他并发症或不良事件。
- 穿刺证实2例患者存在有临床意义的前列腺癌。
- 共30个穿刺位点,机器人基于磁共振的靶向精度为2.55毫米,垂直于针的精度为1.59毫米,无需轨迹修正,无穿刺位点尝试失败。
临床怎么用
- 作者认为机器人辅助磁共振引导下前列腺穿刺活检看似安全可行。
- 作者认为直接在可疑癌灶确认针尖位置可能优于融合技术,并提高阴性活检的可信度。
- 作者认为需进一步研究评估该方法的疗效。
局限性
- 本研究并非为检测前列腺癌而设计。
- 需进一步研究评估该方法的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate safety and feasibility in a first-in-human trial of a direct magnetic resonance imaging (MRI)-guided prostate biopsy using a novel robotic device. METHODS: MrBot is an MRI-safe robotic device constructed entirely with nonconductive, nonmetallic, and nonmagnetic materials and developed by our group. A safety and feasibility clinical trial was designed to assess the safety and feasibility of a direct MRI-guided biopsy with MrBot and to determine its targeting accuracy. Men with elevated prostate-specific antigen levels, prior negative prostate biopsies, and cancer-suspicious regions (CSRs) on MRI were enrolled in the study. Biopsies targeting CSRs, in addition to sextant locations, were performed. RESULTS: Five men underwent biopsy with MrBot. Two men required Foley catheter insertion after the procedure, with no other complications or adverse events. Even though this was not a study designed to detect prostate cancer, biopsies confirmed the presence of a clinically significant cancer in 2 patients. On a total of 30 biopsy sites, the robot achieved an MRI-based targeting accuracy of 2.55 mm and a precision of 1.59 mm normal to the needle, with no trajectory corrections and no unsuccessful attempts to target a site. CONCLUSION: Robot-assisted MRI-guided prostate biopsy appears safe and feasible. This study confirms that a clinically significant prostate cancer (≥5-mm radius, 0.5 cm3) depicted in MRI may be accurately targeted. Direct confirmation of needle placement in the CSR may present an advantage over fusion-based technology and gives more confidence in a negative biopsy result. Additional study is warranted to evaluate the efficacy of this approach.
引用
- Ball MW, Ross AE, Ghabili K, et al. Safety and Feasibility of Direct Magnetic Resonance Imaging-guided Transperineal Prostate Biopsy Using a Novel Magnetic Resonance Imaging-safe Robotic Device. Urology. 2017. PMID: 28735018. doi:10.1016/j.urology.2017.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。